Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of High-Dose Rosuvastatin Combined With Telmisartan or Amlodipine on Glucose Metabolism in Atherosclerotic Cardiovascular Disease (ASCVD) Patients With Impaired Fasting Glucose (IFG) and Hypertension: A Randomized, Open-Label, Parallel, Prospective Study

NCT03474562 is registered in ClinicalTrials.gov with Yuhan Corporation as lead sponsor.

NCT NCT03474562
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03474562 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of High-Dose Rosuvastatin Combined With Telmisartan or Amlodipine on Glucose Metabolism in Atherosclerotic Cardiovascular Disease (ASCVD) Patients With Impaired Fasting Glucose (IFG) and Hypertension: A Randomized, Open-Label, Parallel, Prospective Study
Lead sponsor
Yuhan Corporation
Phase
Phase 4
Overall status
Completed
Start date
April 3, 2018
Completion date
June 7, 2019
Enrollment
100 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

ascvd, hypertension, impaired fasting glucose